文献速递白血病

维奈克拉联合低甲基化药物在急性髓系白血病中的应用:梅奥诊所86例患者系列研究

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
PubMed 文献 · Am J Hematol · 2020-09-16

本研究回顾梅奥诊所86例急性髓系白血病(AML)患者使用维奈克拉联合低甲基化药物(HMA)的机构经验。初治44例中完全缓解/完全缓解伴血细胞计数不完全恢复(CR/CRi)率为50%,优于匹配HMA单药组的23%(P=0.005);复发/难治42例中CR/CRi率为33.3%,达CR/CRi者生存延长。

要点

  • 初治AML患者维奈克拉联合HMA的CR/CRi率为50%(22/44),优于匹配HMA单药组的23%(P=0.005)。
  • 复发/难治AML患者中33.3%(14/42)达CR/CRi,达CR/CRi者中位生存15个月 vs 未达者3个月(P<0.001)。
  • 初治患者达CR/CRi者中位生存17个月 vs 未达者3个月(P<0.001);不良ELN风险预示生存较差。

核心结论

  • 维奈克拉联合HMA在初治和复发/难治AML患者中均显示较好缓解率和生存延长,与基因型无关;作者识别出独特的缓解预测因素,但需验证。

研究设计与样本

  • 梅奥诊所机构经验系列,纳入86例初治和复发/难治AML患者,接受维奈克拉联合HMA治疗,分析缓解、生存结局及其决定因素。
  • 初治组44例,中位年龄73.5岁,其中继发性、治疗相关和ELN不良风险疾病27例。
  • 复发/难治组42例,半数接受过≥2线 prior therapy(排除移植),15例(35.7%)曾接受HMA。

主要发现

  • 初治组CR/CRi率为50%(22/44),匹配HMA单药组为23%(P=0.005);TP53、FLT3、NPM1和IDH突变间缓解率相似(P=0.31)。
  • 初治组中CEBPA突变(P=0.03)和中性粒细胞减少(P=0.05)为完全缓解的预测因素;达CR/CRi者中位生存17个月 vs 未达者3个月(P<0.001);不良ELN风险预示生存较差。
  • 复发/难治组CR/CRi率为33.3%(14/42);年龄>65岁、伴骨髓增生异常特征的AML、JAK2、DNMT3A和BCOR突变预测完全缓解。
  • 复发/难治组达CR/CRi者中位生存15个月 vs 未达者3个月(P<0.001);TP53突变状态与生存差异相关(P=0.04)。

局限性

  • 作者指出所识别的独特缓解预测因素需要验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax and hypomethylating agent (HMA) combination therapy is FDA-approved for elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive chemotherapy. The primary objective of the current study was to impart our institutional experience with the above regimen, outlining response, survival outcomes, and its determinants amongst 86 treatment- naïve and relapsed/refractory AML patients. A total of 44 treatment-naïve AML patients, median age 73.5 years, enriched with secondary, therapy related and ELN adverse risk disease (n = 27) were studied. The CR/CRi rates of 50% (22 of 44 patients) were superior to 23% in a matched AML cohort treated with HMA alone (P = .005). Response rates were similar with TP53, FLT3, NPM1 and IDH mutations (P = .31). Moreover, CEPBA mutations (P = .03) and neutropenia (P = .05) emerged as predictors of complete response. Survivalwas prolonged in patients achieving CR/CRi (17 vs 3 months without CR/CRi, P < .001; conversely adverse ELN risk portended inferior survival. Amongst 42 relapsed/refractory AML patients, half received ≥2 prior therapies excluding transplant, and 15 (35.7%) had received HMA. A group of 14 patients (33.3%) attained CR/CRi; age > 65 years, AML with myelodysplasia, JAK2, DNMT3A, and BCOR mutations predicted complete response. Survival distinctions were based on CR/CRi (median survival 15 vs 3 months with/without CR/CRi; P < .001), and TP53 mutation status (P = .04). In summary, we corroborate existing reports demonstrating superior response and prolonged survival with venetoclax and HMA in treatment -naïve and relapsed/refractory AML patients regardless of genotype. Additionally, we identify unique predictors of response to therapy which require validation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020. PMID: 32833294. doi:10.1002/ajh.25978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。